/758,173	ANDERSON ET AL.	
aminer	Art Unit	
illip Gambel	1644	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>11/26/03</u> .		
2. The allowed claim(s) is/are 23, 24, 26, 32, 37 renumbered 1-5.		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
6. ☐ Interview Summary Paper No./Mail Dat 7. ☐ Examiner's Amendr	(PTO-413), te nent/Comment ent of Reasons for Allo Phillip Gambel Primary Examiner	
	on the cover sheet with this application is subject to she sheet application is subject to she sheet shee	on the cover sheet with the correspondence address REMAINS) CLOSED in this application. If not include ther appropriate communication will be mailed in due in the application is subject to withdrawal from issuest in MPEP 1308. 35 U.S.C. § 119(a)-(d) or (f). Sen received. Sen received in Application No Sents have been received in this national stage applications are the attached EXAMINER'S AMENDMENT or Neason(s) why the oath or declaration is deficient. Sentent Drawing Review (PTO-948) attached sendent or in the Office action of the eader according to 37 CFR 1.121(d). Sentent DEPOSIT OF BIOLOGICAL MATERIAL Sentent Deposit Of Biological Material. Sentent Deposit Of Biol

Application/Control Number: 09/758,173

Art Unit: 1644

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on 11/26/03 has been entered.

Claims 23 and 32 have been amended.

Claims 1-22, 25, 27-31 and 33-36 have been canceled.

Claims 23, 24, 26, 32 and 37 are pending in the instant application.

REASONS FOR ALLOWANCE

2. The following is an Examiner's Statement of Reasons for Allowance:

As indicated previously, the specific B7.1-specific antibodies 7C10, 7B6 and 16C10 appear to be free of the prior art and, in turn, the claimed methods of treating B cell lymphoma with said antibodies are deemed allowable.

- 3. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Phillip Gambel, PhD. Primary Examiner Technology Center 1600

March 1, 2004

PHILLIP GAMPE